

Expeditious Route to F unit Building Block of Moenomycin A

Ramesh Kakarla*, Manuka Ghosh, Jan A. Anderson, Richard G. Dulina and Michael J. Sofia

Intercardia Research Laboratories, 8 Cedar Brook Drive, Cranbury, NJ 08852

Received 18 September 1998; revised 13 October 1998; accepted 16 October 1998

Abstract: Synthesis of the versatile F sugar unit building block of moenomycin A, Phenyl 2-O-levulinoyl-4-C-methyl-1-thio-β-D-glucopyranosiduronic acid is described starting from phenyl 1-thio-β-D-galactopyranoside. The key synthetic steps included: (I) Regioselective protection of the 3-OH group of phenyl 6-O-trityl-1-thio-β-D-galactopyranoside as its TBDMS ether, (ii) TBAF mediated TBDMS group migration from the C-3 to C-2 position of phenyl 3-O-TBDMS-4-C-methyl-6-O-trityl-1-thio-β-D-galactopyranoside, and (iii) Selective deprotection of TBDMS and trityl groups in phenyl 2-O-levulinoyl-3-O-TBDMS-4-C-methyl-6-O-trityl-1-thio-β-D-glucopyranoside by DDQ. © 1998 Elsevier Science Ltd. All rights reserved.

Moenomycin A^1 (1, Figure 1) belongs to the moenomycin family of phosphoglycolipid antibiotics,² and is a potent inhibitor of bacterial cell wall peptidoglycan biosynthesis.³ Moenomycin A is the major and most active constituent of animal nutritional product² Flavomycin^R. The disaccharide 2^4 (Figure 1) is the smallest fragment of moenomycin A, which retains the full biological activity of the parent compound. Further studies⁵ on the degradation products of 1 revealed the moenuronamide part (F unit with phospholipid) shows some antibacterial activity. However, degradation products of moenomycin C_1 and A_{12} , which contain a galacturonamide moiety as the F unit, revealed that the trisaccharides 3^6 and 4^7 (Figure 1) were the minimum structures required for biological activity.

Figure 1

In order to probe the structure-activity relations of Moenomycin A degradation product 2 through a combinatorial library, we required a suitable protected F unit building block. We envisioned the moenuronamide compound 5 as a versatile building block to generate a three dimensional library. Diversity at C_1 , C_2 and C_3 hydroxyl positions of compound 5 was expected to arise by introducing various phospholipids, monosaccharides and carbamate functionalities at respective positions (Figure 2). The existing synthetic methods⁸ for the preparation of 4-C-methyl glucopyranosiduronic acid derivatives were not suitable to prepare the required building block 5. In this communication, we present a novel and efficient method for the synthesis of compound 5 starting from phenyl 1-thio- β -D-galactopyranoside⁹ (6).

Figure 2

Tritylation of phenyl 1-thio-β-D-galactopyranoside (6) in pyridine and DMAP at 120 °C for 6h furnished 6-O-trityl compound 7 in quantitative yield. Selective protection of the 3-OH group in compound 7 as its TBDMS (tert-butyldimethylsilyl) ether using TBDMSCl and imidazole in DMF for 2h at rt afforded the 3-O-TBDMS derivative 8 in 80% yield along with 10% of the 2-O-TBDMS derivative 8a, and trace amounts of the 2,4-di-O-TBDMS derivative 8b. The structures of 8, 8a and 8b were confirmed by conversion into their corresponding acetates. Regioselective acetylation of 3-O-TBDMS derivative 8 with Ac₂O and DMAP in pyridine at 0°C to 10°C gave us the 2-O-acetyl derivative 9 in quantitative yield. The structure of the 2-O-acetylated compound 9 was confirmed by its ¹H NMR, ¹⁰ which showed one CH₃ signal at 2.10 ppm and a deshielded H-2 proton signal as a triplet at 5.16 ppm, PDC oxidation of the 4-OH group in compound 9 furnished the ulose derivative 10 in 75% yield. Grignard reaction of ulose derivative 10 with MeMgCl in the presence of CeCl₃ in toluene at -78°C to rt resulted in 3:1 ratio (80% yield) of phenyl 3-O-TBDMS-4-C-methyl-6-O-trityl-1-thio-B-Dglucopyranoside (11) and phenyl 4-C-methyl-6-O-trityl-1-thio-β-D-galac-topyranoside (12) (Scheme 1). The stereochemical configuration at C-4 of 4-C-methyl-gluco derivative 11 and 4-C-methyl-galacto derivative 12 was confirmed by ¹³C NMR, ¹¹ which showed characteristic 4-C-Methyl carbon signals¹² at 15.77 and 20.65ppm, respectively.

The 4-C-methyl-gluco derivative 11 when treated with TBAF¹³ at rt for 15 min resulted in TBDMS group migration to give compound 13 in 90% yield. The 3-OH group in compound 13 was converted in 85% yield to its levulinoyl ester 14 by treatment with levulinic acid, DCC and DMAP in dichloromethane at refluxing conditions for 10 h. Simulta-

Scheme 1: (i) TrCl, Py, DMAP, 120 0 C, 6 h; (ii) TBDMSCl, imidazole, DMF, rt, 2 h; (iii) Ac₂O, Py, DMAP, 0 0 C to 10 0 C, 1 h; (iv) PDC, Ac₂O, CH₂Cl₂, reflux, 2 h; (v) MeMgCl, CeCl₃, Toluene, -76 0 C to rt, 14h

neous deprotection of trityl and TBDMS protecting groups in compound 14 was achieved by modifying the existing DDQ catalyzed TBDMS deprotection protocol. Refluxing compound 14 with 0.5 equivalents of DDQ in 90% aqueous acetonitrile for 4 h gave compound 16 in 70% yield along with a 15% yield of phenyl 2-O-TBDMS-3-O-Levu-linoyl-4-C-methyl-1-thio-β-D-glucopyranoside (15). Jones oxidation of 3-O-levulinoyl-4-C-methyl-glucopyranoside derivative 16 furnished 5 in 65% yield (Scheme 2). The structure of compound 5 was confirmed by H NMR, I3C NMR, MS and elemental analysis. 16

Scheme 2: (i) TBAF, THF, rt, 15 min; (ii) Levulinic acid, DCC, DMAP, CH₂Cl₂, reflux, 24 h; (iii) 90% aq. CH₃CN, DDQ, 90 °C, 4 h; (iv) Jones reagent, acetone, sonication, 30 °C, 1 h

In conclusion, we developed an expeditious (17% overall yield) route to F Unit building block (5) of Moenomycin A. This versatile building block 5 will be used as an acceptor in the construction of a combinatorial library based on the disaccharide phosphoglycolipid 2. The selective protection of compounds 8 and 9 with TBDMS and acetate groups should find general utility for carbohydrate building block synthesis. We have also demonstrated for the first time that in the presence of a thiophenyl group and a levulinoyl ester, DDQ is useful in deprotecting TBDMS and trityl groups from carbohydrate molecules.

References and notes

- a) Welzel, P.; Witteler, F.-J.; Muller, D.; Riemer, W. Angew. Chem. Int. Ed. Engl. 1981, 20, 121-123. b)
 Welzel, P.; Wietfeld, B.; Kunisch, F.; Schubert, T.; Hobert, K.; Duddeck, H.; Muller, D.; Huber, G.; Maggio, J. E.; Williams, D. H. Tetrahedron 1983, 39, 1583-1591, and references cited therein.
- 2. Huber, G. Antibiotics; (Ed.) Hahn, F. E.; Springer: Berlin; 1979, vol 5, 135-153.
- 3. van Heijenoort, J.; van Heijenoort, Y.; Welzel, P. Antibiotic Inhibition of Bacterial Cell Wall Surface Assembely and Function; (Eds.) Actor, P.; Danco-Moore, L.; Higgins, M. L.; Salton, M. R. J.; Shockman, G. D.; American Society for Microbiology: Washington, 1988, 549-557.
- 4. Welzel, P.; Kunisch, F.; Kruggel, F.; Stein, H.; Scherkenbeck, J.; Hiltmann, A.; Duddeck, H.; Muller, D.; Maggio, J. E.; Fehlhaber, H. -W.; Siebert, G.; van Heijenoort, Y.; van Heijenoort, J. Tetrahedron 1987, 43, 585-598.
- 5. Fehlhaber, H.-W.; Girg, M.; Seibert, G.; Hobert, K.; Welzel, P.; van Heijenoort, Y.; van Heijenoort, J. Tetrahedron 1990, 46, 1557-1568.
- 6. Hebler-Klintg, M; Hobert, K.; Biallab, A.; Siegels, T.; Hiegemann, M.; Maulshagen, A.; Muller, D.; Welzel, P.; Huber, G.; Bottger, D.; Markus, A.; Seibert, G.; Stark, A.; Fehlhaber, H.-F.; van Heijenoort, Y.; van Heijenoort, J. *Tetrahedron* 1993, 49, 7667-7678.
- 7. Donnerstag, A.; Marzian, S.; Muller, D.; Welzel, P. Tetrahedron 1995, 51, 1931-1940.
- a) Sato, K.-I.; Kubo, K.; Hong, N.; Kodama, H.; Yoshimura, J. J. Bull. Chem. Soc. Jpn. 1982, 55, 938-942.
 b) Welzel, P.; Bulian, H.-P.; Maulshagen, A.; Muller, D.; Snatzke, G. Tetrahedron 1984, 40, 3657-3666.
 c) Plewe, M.; Sandhoff, K.; Schmidt, R. R. Carbohydrate Res. 1992, 235, 151-161.
 d) Hansson, T. G.; Plobeck, N. A. Tetrahedron 1995, 51, 11319-11326.
- 9. a) Ferrier, R. J.; Furneaux, R. H. Carbohydrate Res. 1976, 52, 63-68. b) Sarkar, A. K.; Matta, K. L. Carbohydrate Res. 1992, 233, 245-250.
- 10. Compound 9: ${}^{1}H$ NMR (CDCl₃ + 2 drops D₂O): δ 7.60-7.10 (m, 5H), 5.16 (t, J = 9.6Hz, 1H), 4.54 (d, J = 9.6Hz, 1H), 3.75-3.50 (m, 4H), 3.28-3.22 (m, 1H), 2.10 (s, 3H), 0.85 (s, 9H), 0.06 and 0.05 (each s, 6H).
- 11. a) Compound 11: 1 H NMR (CDCl₃ + 2 drops D₂O) δ 7.70-7.20 (m, 5H), 4.61 (d, J = 9.6Hz, 1H), 3.52-3.40 (m, 3H), 3.26-3.16 (m, 2H), 0.90 (s, 3H), 0.85 (s, 9H), 0.09 and 0.07 (each s, 6H). Selected peaks in 13 C NMR (CDCl₃) δ 88.89, 87.05, 81.51, 81.1973.09, 71.70, 62.66, 25.93, 18.34, 15.77 (4-C-Me), -4.40 and -4.73. b) Compound 12: 1 H NMR (CDCl₃ + 2 drops D₂O) δ 7.69-7.22 (m, 5H), 4.56 (d, J = 9.6Hz, 1H), 3.65 (t, J = 9.6Hz), 3.57-3.25 (m, 3H), 3.17 (d, J = 9.6Hz, 1H), and 0.95 (s, 3H). Selected peaks in 13 C NMR (CDCl₃ + 2 drops D₂O) δ 88.20, 87.12, 81.34, 78.08, 73.14, 70.35, 62.95, 20.65 (4-C-Me).
- a) Miljkovic, M.; Gligorijevic, M. Satoh, T.; Miljkovc, D. J. Org. Chem. 1974, 10, 1379-1384. b) Miljkovic, M.; Gligorijevic, M. Satoh, T.; Glisin, D. J. Org. Chem. 1974, 26, 3847-3850.
- a) Wuts, P. G. M.; Bigelow, S. S. J. Org. Chem. 1988, 53, 5023-5034. b) Franke, F.; Guthrie, R. D. Aust. J. Chem. 1978, 31, 1285-1290. c) Torisawa, Y.; Shibasaki, M.; Ikegami, S. Tetrahedron Lett. 1979, 21, 1865-1868. d) Ogilvie, K. K.; Beaucage, S. L.; Schifman, A. L.; Theriault, N. Y.; Sadana, K. L. Can. J. Chem. 1978, 56, 2768-2780. e) Jones, S. S.; Reese, C. B. J. Chem. Soc., Perkin Trans. I 1979, 2762-2764. f) Ogilvie, K. K.; Entwistle, D. W. Carbohydrate Res. 1981, 89, 203-210.
- 14. Tanemura, K.; Suzuki, T.; Horaguchi, T. J. Chem. Soc. Perkin Trans. I 1992, 2997-2998.
- 15. Allanson, N. A.; Liu, D.; Chi, F.; Jain, R. K.; Chen, A.; Ghosh, M.; Hong, L.; Sofia, M. J. Tetrahedron Lett. 1998, 39, 1889-1892.
- 16. Compound 5: mp, $60-62^{-0}$ C; TLC (CH₂Cl₂ / MeOH, 4:1) R_f = 0.2.; MS (EI): 416 (M+NH₄)⁺; Elemental analysis, Calc: C, 54.26; H, 5.57; S, 8.05. Found: C, 54.45; H, 5.68; S, 7.98. ¹H NMR (CD₃OD) δ 7.53-7.18 (m, 5H), 4.95 (d, J = 9.6Hz, 1H), 4.62 (d, J = 9.6Hz, 1H), 3.85 (br s, 1H), 3.21 (t, J = 9.6Hz, 1H), 2.03 (s, 3H) and 1.04 (s, 3H).; ¹³C NMR (CD₃OD) δ 16.73, 29.05, 29.78, 38.73, 70.40, 73.38, 81.55, 89.05, 129.08, 130.10, 132.36, 133.54, 134.35, 173.87, 208.61.